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Abstract
Introduction Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists (DAs) in neurologi-
cal as well as endocrine conditions. Few studies have evaluated the neuropsychological effect of DAs in hyperprolactinemic 
patients, and these have reported a relationship between DAs and ICDs. Our objective was to screen for ICD symptoms in 
individuals with DA-treated endocrine conditions.
Materials and methods A cross-sectional analysis was conducted on 132 patients with pituitary disorders treated with DAs 
(DA exposed), as well as 58 patients with pituitary disorders and no history of DA exposure (non-DA exposed). Participants 
responded to the full version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s disease (QUIP).
Results Compared with the non-DA-exposed group, a higher prevalence of DA-exposed patients tested positive for symptoms 
of any ICD or related behavior (52% vs. 31%, p < 0.01), any ICD (46% vs. 24%, p < 0.01), any related behavior (31% vs. 17%, 
p < 0.05), compulsive sexual behavior (27% vs. 14%, p < 0.04), and punding (20% vs. 7%, p < 0.02) by QUIP. On univariate 
analysis, DA treatment was associated with a two- to threefold increased risk of any ICD or related behavior [odds ratio (OR) 
2.43] and any ICD (OR 2.70). In a multivariate analysis, independent risk factors for any ICD or related behavior were DA use 
(adjusted OR 2.22) and age (adjusted OR 6.76). Male gender was predictive of the risk of hypersexuality (adjusted OR 3.82).
Discussion Despite the QUIP limitations, a clear sign of increased risk of ICDs emerges in individuals with DA-treated 
pituitary disorders. Our data contribute to the growing evidence of DA-induced ICDs in endocrine conditions.
Keywords Impulse control disorders · Dopamine agonists · Cabergoline · Hyperprolactinemia · Pituitary adenoma · QUIP 
questionnaire
Introduction
Impulse control disorders (ICDs) are psychopathological 
conditions characterized by difficulty resisting urges to 
engage in behaviors that are excessive and potentially harm-
ful to oneself or others [1]. These disorders can cause sig-
nificant impairment in social and occupational functioning, 
as well as legal and financial difficulties [1]. The four major 
ICDs are pathological gambling, hypersexuality, compulsive 
buying/shopping, and binge eating [2].
ICDs have been described as a side effect of treatment 
with dopamine agonists (DAs) since 2000, when the first 
cases of pathological gambling were reported in patients 
treated for Parkinson’s disease (PD) [3]. Up to 20% of PD 
patients experience ICDs over the course of their illness [4]. 
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An increased frequency of ICDs has been also described in 
individuals with restless leg syndrome treated with DAs [5].
Pharmacological stimulation by DAs of the D3 dopamine 
receptors in the mesocorticolimbic dopaminergic pathway 
seems to be the mechanism underlying the activation of the 
reward system that leads to ICDs [6].
DAs are also used to treat endocrine conditions, such as 
prolactin (PRL)-secreting adenoma, growth hormone (GH)- 
and GH/PRL-secreting adenoma, non-functioning pituitary 
adenoma, and idiopathic hyperprolactinemia. Therapy 
with DA aims to reduce levels of PRL and, in the case of 
adenoma, to induce tumor shrinkage. The dose of DA is 
generally lower for endocrine conditions (e.g., cabergoline 
0.25–3.0 mg/week, up to 11 mg/week in resistant patients) 
than that used to treat PD [7]. Nevertheless, some cases of 
ICDs have been reported in prolactinomas treated with DA 
[8–14]. Only a few cross-sectional studies [15–17] and one 
prospective study [18] have evaluated the neuropsychologi-
cal effect of DAs in hyperprolactinemic subjects; these stud-
ies found a relationship between DAs and ICDs.
The present study aimed to screen for ICDs and related 
behavior symptoms in patients with DA-treated endo-
crine conditions through a neuropsychological screening 
questionnaire.
Materials and methods
This was an observational cross-sectional study includ-
ing 180 patients enrolled in the outpatient neuroendocrine 
clinic of the “City of Health and Science of Turin” Uni-
versity Hospital (Turin, Italy) from October 2016 through 
February 2019. Of these, 132 patients were affected by 
functional hyperprolactinemia or PRL-, GH-, or GH/PRL-
secreting adenoma with present or past use of DAs, defined 
as DA exposed; cabergoline was the only DA employed in 
the study. The reference group consisted of 58 patients with 
functional hyperprolactinemia or PRL, GH-, or GH/PRL-
secreting adenoma never treated with DAs or with hypotha-
lamic/pituitary disease without hyperprolactinemia, defined 
as non-DA exposed. Exclusion criteria were a history of PD 
and known psychiatric illness. Clinical information was col-
lected through a review of medical records and during the 
survey.
All participants in the DA-exposed and non-DA-exposed 
groups completed the following self-administered, validated 
neuropsychological tools: (1) the full version of the Ques-
tionnaire for Impulsive-Compulsive Disorders in Parkinson’s 
disease (QUIP) to screen for symptoms of ICDs (compul-
sive gambling, compulsive sexual behavior, compulsive buy-
ing, compulsive eating) and related behaviors (hobbyism, 
punding, walkabout) [19]. The Italian QUIP version herein 
employed was used in an international, multicenter study on 
Parkinson’s disease patients [20], with the questionnaire’s 
last section on PD medication modified to non-PD medica-
tion. The full version assessed ICDs not only currently but 
also any time during DA treatment, to include in the analysis 
those who discontinued cabergoline. (2) Test Your Memory 
was used to evaluate intellectual efficiency [21] and exclude 
severe cognitive impairment. Lastly, (3) the validated Ital-
ian version of the Hospital Anxiety and Depression Scale 
(HADS) was used to assess the presence of anxiety and 
depressive symptoms [22].
Data are presented as medians (first and third quartiles) 
for skewed variables. Statistical analysis was performed 
using the Stata program (version 15; StataCorp LLC, Col-
lege Station, TX, USA). The DA-exposed and non-DA-
exposed groups were compared using the Mann–Whitney 
U test for continuous variables and using the chi-squared 
and Fisher tests for categorical variables.
Multivariate analysis was performed using a logistic 
regression model, after logarithmic transformation of all 
variables with a skewed distribution. A p value < 0.05 was 
considered statistically significant.
The study was approved by the local ethics committee. 
All patients gave written informed consent.
Results
The population characteristics are summarized in Table 1. In 
the DA-exposed group, the median age was 40.5 years (27.5, 
52.0) at diagnosis and 48.9 years (39.1, 62.7) at question-
naire completion; 58% were women. At study enrollment, 
current medications included DAs for 81% of DA-exposed 
individuals; 19% had previously discontinued DA treatment. 
Median weekly cabergoline dose was 1 mg (0.75, 1.5) and 
median treatment duration was 4 years (1.5, 8).
Compared with the DA exposed, the non-DA exposed 
had a higher median age at the time of diagnosis (52.0 years; 
38.5, 66.0; p < 0.01) and of questionnaire completion 
(66.8 years; 52.0, 73.1; p < 0.01), as well as a trend toward 
a lower percentage of women (43%; p = 0.06).
Hyperprolactinemia (PRL levels > 25  ng/mL) was 
observed in 84% of the DA exposed. Of these, 90% had 
PRL levels within a normal range after DA therapy. Nor-
mal PRL, testosterone, and both PRL and testosterone levels 
were found in 85%, 80%, and 76% of male DA exposed, 
respectively, after DA alone or in combination with testos-
terone replacement therapy.
In the non-DA-exposed group, only 18% of patients had 
hyperprolactinemia. Of these, 90% had PRL levels within 
a normal range, spontaneously or after neurosurgery; one 
subject had borderline-elevated PRL values without the need 
for DA treatment.
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The results of the QUIP screening are summarized in 
Table 2.
Compared with the reference group, the DA-exposed 
individuals showed a higher prevalence of compulsive 
sexual behavior (27% vs. 14%; p < 0.04) and punding (20% 
vs. 7%; p < 0.02), as well as a trend toward a higher preva-
lence of compulsive buying (18% vs. 9%; p < 0.07) and 
compulsive eating (22% vs. 12%; p < 0.08), but no differ-
ence in compulsive gambling (6% vs. 3%; NS), hobbyism 
(21% vs. 14%; NS), walkabout (8% vs. 5%; NS), excessive 
amount of time spent on impulsive behaviors (7% vs. 3%; 
NS), difficulty in controlling the amount of time spent on 
impulsive behaviors (8% vs. 5%; NS), or non-PD excess 
therapy (4% vs. 3%; NS).
Table 1  Clinical characteristics 
of dopamine agonist-exposed 
and non-exposed individuals
Data are presented as the median (interquartile range)
DA = dopamine agonist
DA exposed = patients with pituitary disorders treated with dopamine agonist
Non-DA exposed = patients with pituitary disorders and no history of dopamine agonist exposure
DA exposed (n = 132) Non-DA exposed (n = 58) p value
Gender
 Men 42% 57% 0.06
 Women 58% 43%
Age at diagnosis, years 40.5 (27.5–52.0) 52.0 (38.5–66.0)  < 0.01
Age at the time of questionnaires, years 48.9 (39.1–62.7) 66.8 (52.0–73.1)  < 0.01
Hyperprolactinemia 84% 18%
DA treatment Current: 81%
Previous: 19%
Cabergoline weekly dose, mg 1 (0.75–1.5); max 6.5
DA treatment duration, years 4 (1.5–8); max 31
Table 2  Prevalence of impulse control disorders and related behavior symptoms in dopamine agonist-exposed and non-exposed individuals
DA = dopamine agonist
DA exposed = patients with pituitary disorders treated with dopamine agonist








Compulsive gambling 6% 3% p = 0.36
Compulsive sexual behavior 27% 14% p < 0.04
Compulsive buying 18% 9% p < 0.07
Compulsive eating 22% 12% p < 0.08
Positive screening for any impulse control disorder 46% 24% p < 0.01
Unadjusted OR 2.70 (95% CI 1.35–5.39)
Other related behaviors
Hobbyism 21% 14% p = 0.17
Punding 20% 7% p < 0.02
Walkabout 8% 5% p = 0.53
Positive screening for any behavior 31% 17% p < 0.05
Unadjusted OR 2.16 (95% CI 1.00–4.69)
Excessive amount of time spent on impulsive behaviors 7% 3% p = 0.28
Difficulty in controlling the amount of time spent on impulsive behaviors 8% 5% p = 0.32
Excess medication use 4% 3% p = 0.92
Impulse control disorders and related behaviors
Positive screening for any impulse control disorder or behavior 52% 31% p < 0.01
Unadjusted OR 2.43 (95% CI 1.26–4.67)
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The proportion of patients screening positive for any 
ICD was higher in the DA-exposed compared with the non-
exposed individuals (46% vs. 24%; p < 0.01; unadjusted OR 
2.70, 95% CI 1.35–5.39), as well as for any related behav-
ior (31% vs. 17%; p < 0.05, unadjusted OR 2.16, 95% CI 
1.00–4.69). When considering ICDs and related behaviors 
together, the percentage of patients screening positive for 
any ICD or related behavior was 52% of the DA-exposed 
and 31% of the non-DA-exposed individuals (p < 0.01; unad-
justed OR 2.43, 95% CI 1.26–4.67).
In a stratified analysis of DA-exposed men, compared 
with individuals not achieving normal levels of PRL and 
testosterone, those with a combined restoration of both 
hormones did not show a higher prevalence of compulsive 
sexual behavior (42% vs. 23%; NS), positive screening for 
any ICD (57% vs. 38%; NS), or positive screening for any 
ICD or related behavior (62% vs. 46%; NS).
Several models of logistic regression were used to iden-
tify predictors of any ICD or related behavior (Table 3a). 
After adjusting for gender, screening positivity was asso-
ciated with DA treatment (β 0.37; adjusted OR 2.1, 95% 
CI 1.06–4.26) and age as a continuous variable (β 0.03; 
per change in regressor over the entire range: adjusted OR 
6.65, 95% CI 1.58–30.06). The association remained sig-
nificant after adjusting for the HADS depression score. In 
an unadjusted analysis, screening positivity was associ-
ated with DA duration but not dose; however, this asso-
ciation did not remain significant after adjusting for age 
and gender.
Compulsive sexual behavior was independently associ-
ated with DA treatment (β 0.48; adjusted OR 2.62, 95% CI 
1.07–7.18), male gender (β 0.67; adjusted OR 3.82, 95% CI 
1.71–9.03), and age as a continuous variable (β 0.02; per 
change in regressor over the entire range: adjusted OR 6.16, 
Table 3  Logistic regression models
OR odds ratio, DA dopamine agonist
Predictor Beta p value
(a) Predicted variable: positive screening for any impulse control disorder or related behavior
Model 1 (n = 190)
Gender (women vs. men) 0.31 < 0.06
Age 0.03 < 0.02 Per change in regressor over the entire range:
Adjusted OR 6.65 (95% CI 1.58–30.06)
DA treatment (no vs. yes) 0.37 < 0.04 Adjusted OR 2.10 (95% CI 1.06–4.26)
Model 2 (n = 179)
Gender (women vs. men) 0.31 < 0.08
Age 0.03 < 0.02 Per change in regressor over the entire range:
Adjusted OR 6.76 (95% CI 1.50–33.01)
DA treatment (no vs. yes) 0.40 < 0.03 Adjusted OR 2.22 (95% CI 1.10–4.26)
HADS-Depression score − 0.04 0.40
Model 3 (n = 131)
DA dose − 0.02 0.87
Model 4 (n = 132)
DA treatment duration 0.34 < 0.05 Per unit change in regressor: OR 1.40 (95% CI 1.01–1.96)
Model 5 (n = 131)
Gender (women vs. men) 0.36 0.09
Age 0.03 < 0.03 Per change in regressor over the entire range:
Adjusted OR 8.76 (95% CI 1.42–63.02)
DA dose 0.01 0.94
DA treatment duration 0.27 0.13
(b) Predicted variable: positive screening for compulsive sexual behavior
Model 1 (n = 179)
Gender (women vs. men) 0.67 < 0.01 Adjusted OR 3.82 (95% CI 1.70–9.03)
Age 0.02 < 0.05 Per change in regressor over the entire range:
Adjusted OR 6.16 (95% CI 1.03–40.37)
DA treatment (no vs. yes) 0.37 < 0.04 Adjusted OR 2.62 (95% CI 1.07–7.18)
HADS-depression score 0.07 0.44
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95% CI 1.03–40.37), after adjusting for the HADS depres-
sion score (Table 3b).
Discussion
This study revealed that DA treatment for endocrine condi-
tions is associated with a higher risk of testing positive for 
ICDs by QUIP.
Aside from case series published in the literature [8–14], 
only a few endocrinological trials have investigated the rela-
tionship between DA and ICDs.
The first cross-sectional study conducted in the United 
States by Bancos et al. included 77 patients with prolac-
tinomas treated with DA and 70 patients with DA-naïve, 
non-functioning pituitary adenomas [15]. The use of DA 
was associated with an increased rate of hypersexuality but 
not with the overall prevalence of ICDs. Interestingly, men 
with prolactinomas treated with DAs showed an unadjusted 
OR of 9.9 for any ICD compared with those with non-func-
tioning pituitary adenomas.
A multicenter cross-sectional study included 308 patients 
with DA-treated prolactinoma but lacked a control group 
[16]. A modified QUIP showed a prevalence of 17% of any 
ICD; hypersexuality was most common. Independent predic-
tive factors for ICD were male gender and alcohol use; nadir 
PRL did not reach statistical significance.
Another multicenter cross-sectional study enrolled 113 
DA-treated hyperprolactinemic patients and 99 healthy 
controls [17]. Patients were more likely than controls to 
test positive by the QUIP-Shortened Version for any ICD, 
hypersexuality, compulsive buying and punding, and by the 
Hypersexual Behavior Inventory for hypersexuality. Inde-
pendent risk factors for hypersexuality were male sex, eug-
onadism, lower score of the Hardy’s classification of pitui-
tary adenomas, and psychiatric comorbidity. A higher stress 
score was associated with compulsive buying and punding.
A Turkish prospective study included 25 patients with 
prolactinomas and 63 controls (31 non-functioning pituitary 
adenomas and 32 healthy individuals) [18]. During a 1-year 
follow-up, 8% of the patients with prolactinomas developed 
hypersexuality, which reversed fully or decreased upon dis-
continuation of DA treatment.
Our study represents one of the largest samples described 
in the literature, enrolling patients only from a single, ter-
tiary referral center.
Compared with the reference group, the DA-exposed 
patients were almost 11.5 years younger at diagnosis and 
18 years younger at questionnaire completion. Because there 
was a trend toward a higher prevalence of women in the DA-
exposed group, gender and age were used as covariates in a 
multiple logistic regression.
The DA-exposed individuals were more likely to test 
positive by QUIP for any ICD, any related behavior, any 
ICD or related behavior, compulsive sexual behavior, and 
punding. Trends toward higher rates of compulsive buying 
and compulsive eating were also found in the case group. 
No difference in the prevalence of compulsive gambling, 
hobbyism, walkabout, excessive amount of time spent on 
impulsive behaviors, difficulty in controlling the amount of 
time spent on impulsive behaviors, or non-PD excess therapy 
was found between the two groups.
Independent, positive predictors of any ICD or related 
behavior were DA use and age at questionnaire completion, 
but not male gender, which was an independent risk factor 
for sexual behavior only. The increased ICD risk in older age 
rather than younger age was not in line with previous stud-
ies of the general population, as well as PD and endocrine 
patients. This may be related to the clinical characteristics 
of our specific sample with endocrine disorders and caber-
goline-induced ICDs and is, thus, not applicable in other 
clinical settings. The implications of these findings are still 
unclear, as the impact of age on the type and severity of ICD 
needs further investigation.
After adjusting for confounding factors, DA dose and 
duration did not correlate with the presence of any ICD or 
related behavior. The lack of interaction between DA dose 
and ICD risk is most likely a result of the limited statistical 
approach, because a resolution of ICDs has been described 
after DA dose reduction, not only after DA cessation [14].
To be consistent with a previous study on PD conducted 
by some of us [20], we planned to use the QUIP as a screen-
ing tool for ICD. This questionnaire was validated in a sam-
ple of PD patients undergoing a diagnostic interview by an 
investigator blinded to the QUIP results [19]. The QUIP 
is designed to be sensitive for the detection of ICDs and 
related disorders, but it is not highly specific. In fact, Wein-
traub et al. combined the four ICDs (compulsive gambling, 
compulsive sexual behavior, compulsive buying, compul-
sive eating) to increase the sensitivity to 97% in identifying 
an individual with any ICD. Similarly, they combined the 
ICDs with compulsive behaviors to increase the sensitiv-
ity to 96% in identifying an individual with any disorder/
behavior. The negative predictive values for each ICD were 
very high, whereas the positive predictive values were low 
overall. Thus, with a high degree of certainty, a negative 
screen corresponds to the absence of ICD. To deal with the 
low positive predictive value, an individual who screens 
positive should undergo a clinical interview.
In our study, the high prevalence of positive screens 
could be supported by two hypotheses. First, the QUIP 
cut-off values validated by Weintraub et al. in a PD sample 
might not be adequate in our population, thus leading to an 
overestimation of the actual prevalence of ICDs. Second, 
the different personality profiles observed in patients with 
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non-functioning pituitary adenoma [23] might have influ-
enced the QUIP results in our non-DA-exposed group. It 
would be preferable to have the QUIP validated in an endo-
crine setting; the lack of a follow-up interview represents a 
major issue.
As a screening tool, the QUIP does not provide specific 
information about the severity of ICDs or related behavior 
symptoms. Other authors used a specific questionnaire to 
assess the consequences of hypersexuality [17]. This limita-
tion suggests that a positive screen needs to be followed by a 
clinical interview to verify whether a patient truly has clini-
cally significant ICDs or other compulsive behaviors and 
how severe they are. Another advantage of a clinical inter-
view is to better discriminate between hypersexual diagnosis 
and normal return in libido. Another limitation of the QUIP 
is the exclusion of other impulsive activities that would fit 
a non-neurological clinical setting. For example, De Sousa 
et al. suggested the inclusion of impulsive activities like 
exercise, caffeine consumption, and video game use [17], 
and we propose mobile and social network use, trichotillo-
mania, kleptomania, and nail biting. Also, it would be inter-
esting to assess the ability to focus attention or concentrate, 
as DA-treated hyperprolactinemic patients, compared with 
controls, had a higher attentional impulsiveness subscale 
score, meaning a tendency for quicker impulsive decisions 
or cognitive impulsiveness [24].
Based on the QUIP characteristics, we postulate that this 
screening tool may be of value in detecting subclinical ICD 
symptoms in patients at risk for developing ICDs before 
starting DA treatment; however, this should be confirmed 
in an ad hoc study. Further studies are warranted to validate 
both the English and Italian QUIP in an endocrine setting, 
before and after DA therapy.
Aside from the questionnaire performance, a clear sign of 
increased risk of ICDs emerges in individuals treated with 
DA and appears to be consistent among PD and endocrine 
populations. In fact, the adjusted OR for any ICD or related 
behavior in our study (2.22) was similar to that described in 
PD (2.72) [25]. Also, an increased risk for hypersexuality 
was shown in our sample (adjusted OR 2.62) and in a previ-
ous study (OR 5.07 in the whole group) [15].
The gender difference in the risk of developing hyper-
sexuality or other ICDs raises some interesting questions. As 
male gender is a recognized independent risk factor for ICDs 
[26], we speculate whether this could be due to a different 
neurobiological substrate between men and women, reflected 
in clinical disorders linked to the dopamine system. In the 
human brain, sex differences have been described in the 
extrastriatal dopamine D2 receptors of healthy individuals 
[27] and in the striatal dopamine D2/D3 receptor of smok-
ers and nonsmokers [28]. Moreover, the mesostriatal and 
mesolimbic DA systems of rats show different sensitivities 
to circulating estrogens and androgens, because of specific 
subsets of midbrain DA neurons immunopositive for estro-
gen receptor β or androgen receptors. These findings provide 
an anatomical model with separate effects for androgens and 
estrogens over the mesostriatal and mesolimbic DA systems 
[29]. In summary, gonadal hormones appear to act like neu-
romodulators concurring in the sex differences in impulsive 
and compulsive behaviors [30].
Testosterone has been hypothesized to be permissive 
in the development of any ICD and hypersexuality, but no 
statistical association between hypersexuality and testos-
terone increase has been found [17]. In hypersexual men, 
an independent trend toward higher testosterone was found 
at assessment, but it did not reach statistical significance. 
In our study, normal PRL and testosterone levels were not 
associated with hypersexuality, any ICD, or any ICD or 
related behavior. However, our statistical power was limited, 
because 24% of our patients did not reach normal testoster-
one and PRL levels. It is noteworthy that in the literature, the 
relationship between testosterone and hypersexuality have 
been described as a trend or association that did not persist 
upon multivariate analysis; however, these findings may be 
related to limitations in the study design, the type of con-
trol group, and the lower percentage of men compared with 
women, which would considerably reduce statistical power.
Finally, the cross-sectional nature of the present study 
does not address the direction of causality. A prospective 
study is needed to examine any chronological relation-
ship with the onset of ICD, because the lack of correlation 
between ICDs and duration of DA treatment might be due 
to recall bias, especially for those who had discontinued 
DA treatment. We also believe that the individual threshold 
dose for DA-induced ICDs cannot be addressed by a cross-
sectional section but requires assessment in a longitudinal 
study.
In conclusion, we confirm that DA treatment for endo-
crine conditions is associated with a higher prevalence of 
symptoms of any ICD or related behavior and, separately, 
any ICD, any behavior, compulsive sexual behavior, and 
punding, as well as a trend toward a higher prevalence of 
compulsive buying and compulsive eating, as assessed by 
the full QUIP questionnaire.
Although lower doses of agents with low D3 receptor 
affinity are used in an endocrine setting, the effects are simi-
lar to those seen in PD and restless leg syndrome, confirming 
that ICD development is not related to a preexisting altera-
tion of the dopaminergic system but is secondary to DA 
exposure.
DA use and age were predictive of the risk of any ICD or 
behavior, whereas male gender was predictive of the risk of 
hypersexuality only. DA dose and duration were not associ-
ated with ICD risk.
Although the QUIP is not validated in an endocrine set-
ting and does not provide us with the actual frequency of 
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ICDs as defined by standard criteria, it represents an easy-
to-use, self-administered screening tool.
This large, cross-sectional study from a single, tertiary 
referral center contributes to the growing evidence of DA-
induced ICDs in endocrine conditions.
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